Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Thomas R Jeffry Evans"'
Autor:
Pavlina Spiliopoulou, Farasat Kazmi, Francesca Aroldi, Thomas Holmes, David Thompson, Lucinda Griffiths, Cathy Qi, Matthew Parkes, Simon Lord, Gareth J. Veal, David J. Harrison, Vicky M. Coyle, Jill Graham, Thomas R. Jeffry Evans, Sarah P. Blagden
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)
Abstract Purpose 5-fluorouracil (5-FU) is inefficiently converted to the active anti-cancer metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP), is associated with dose-limiting toxicities and challenging administration schedules. NUC-3373 is a ph
Externí odkaz:
https://doaj.org/article/8de199adb6da4ff4b44e74190f835493
Autor:
Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Publikováno v:
Liver Cancer (2024)
Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs 12.3 months; HR 0.92, 95% CI 0.79-1.06). The objective response rate (ORR
Externí odkaz:
https://doaj.org/article/d6ae54a6e78a47678e598fa918d4b74a
Autor:
Olga Solovyeva, Munyaradzi Dimairo, Christopher J. Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn Richards, Lesley Roberts, John Kirkpatrick, Johann de Bono, Christina Yap
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background Early phase dose-finding (EPDF) trials are crucial for the development of a new intervention and influence whether it should be investigated in further trials. Guidance exists for clinical trial protocols and completed trial repor
Externí odkaz:
https://doaj.org/article/81ef4cb13be84637b253963b7331df99
Autor:
Douglas Cartwright, Stephen Barclay, Adrian Stanley, Neil Lachlan, Ruth Gillespie, Ewan Forrest, Matthew Priest, Andrew Fraser, Michael Johnston, Gregory Naylor, Umberto Pisano, David Kay, Ram Kasthuri, Stuart Ballantyne, Heather Lafferty, Jeffry Evans, Karin Oien, Alistair Stewart McLaren, Johannes A Spoor, Srikanth Puttagunta, Kirsty Armstrong, Thomas R Jeffry Evans, Shouren Datta, Jennifer Milne, Rachel Swann, Adam Wimpress
Publikováno v:
BMJ Open Gastroenterology, Vol 10, Iss 1 (2023)
Objective The COVID-19 pandemic had an undoubted impact on the provision of elective and emergency cancer care, including the diagnosis and management of patients with hepatocellular carcinoma (HCC). Our aim was to determine the effects of the COVID-
Externí odkaz:
https://doaj.org/article/af2dc82f0c164ce388156da1d60df4ce
Autor:
Jessica C Hassel, Mark R Middleton, Alexander N Shoushtari, Omid Hamid, Paolo A Ascierto, Todd M Bauer, John M Kirkwood, Friedegund Meier, Marlana Orloff, Paul C Lorigan, Chris Holland, Cornelia Mauch, Ramakrishna Edukulla, April K S Salama, Thomas R Jeffry Evans, Shaad E Abedin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Immune checkpoint inhibitors have significantly improved outcomes in first line cutaneous melanoma. However, there is a high unmet need for patients who progress on these therapies and combination therapies are being explored to improve ou
Externí odkaz:
https://doaj.org/article/29e4906b8b284394a0be7d5dc9bc48bf
Autor:
Valerio F. Annese, Samadhan B. Patil, Chunxiao Hu, Christos Giagkoulovits, Mohammed A. Al-Rawhani, James Grant, Martin Macleod, David J. Clayton, Liam M. Heaney, Ronan Daly, Claudio Accarino, Yash D. Shah, Boon C. Cheah, James Beeley, Thomas R. Jeffry Evans, Robert Jones, Michael P. Barrett, David R. S. Cumming
Publikováno v:
Microsystems & Nanoengineering, Vol 7, Iss 1, Pp 1-15 (2021)
Abstract There is a global unmet need for rapid and cost-effective prognostic and diagnostic tools that can be used at the bedside or in the doctor’s office to reduce the impact of serious disease. Many cancers are diagnosed late, leading to costly
Externí odkaz:
https://doaj.org/article/d1bc29dd56af41a29ce340058bcb16a7
Autor:
Alexandra Sala, James M. Cameron, Cerys A. Jenkins, Hugh Barr, Loren Christie, Justin J. A. Conn, Thomas R. Jeffry Evans, Dean A. Harris, David S. Palmer, Christopher Rinaldi, Ashton G. Theakstone, Matthew J. Baker
Publikováno v:
Cancers, Vol 14, Iss 13, p 3048 (2022)
Pancreatic cancer claims over 460,000 victims per year. The carbohydrate antigen (CA) 19-9 test is the blood test used for pancreatic cancer’s detection; however, its levels can be raised in symptomatic patients with other non-malignant diseases, o
Externí odkaz:
https://doaj.org/article/0044eb3760254d329d3b81ba81dc25cf
Autor:
Matthew G. Krebs, Jean-Pierre Delord, Thomas R. Jeffry Evans, Maja De Jonge, Sang-We Kim, Marie Meurer, Sophie Postel-Vinay, Jong-Seok Lee, Helen K. Angell, Vidalba Rocher-Ros, Kassondra Meyer, Mei-Lin Ah-See, Pia Herbolsheimer, Zhongwu Lai, Ana Nunes, Susan M. Domchek
Publikováno v:
Krebs, M G, Delord, J-P, Jeffry Evans, T R, De Jonge, M, Kim, S-W, Meurer, M, Postel-Vinay, S, Lee, J-S, Angell, H K, Rocher-Ros, V, Meyer, K, Ah-See, M-L, Herbolsheimer, P, Lai, Z, Nunes, A & Domchek, S M 2023, ' Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, Basket Study ', Lung Cancer, vol. 180, 107216 . https://doi.org/10.1016/j.lungcan.2023.107216
Lung Cancer, 180:107216. Elsevier Ireland Ltd
Lung Cancer, 180:107216. Elsevier Ireland Ltd
Introduction: Preclinical studies have demonstrated increased efficacy with combined DNA damage response inhibition and immune checkpoint blockade compared with either alone. We assessed olaparib in combination with durvalumab in patients with relaps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f55b6a72887c16967c05c789e2f26d5
https://doi.org/10.1016/j.lungcan.2023.107216
https://doi.org/10.1016/j.lungcan.2023.107216
Autor:
Rebecca Kristeleit, Ruth Plummer, Robert Jones, Louise Carter, Sarah Blagden, Debashis Sarker, Tobias Arkenau, Thomas R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Publikováno v:
British Journal of Cancer.
Background This was a first-in-human Phase 1/2 open-label dose-escalation study of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737. Methods Patients with advanced solid tumours enrolled in dose-escalation cohorts and received SRA737 monotherapy
Autor:
Zachary Boyd, Ian Chau, Filippo de Braud, Thomas R. Jeffry Evans, Johanna Bendell, Padmanee Sharma, Patrick A. Ott, Yelena Janjigian, Peter M. Szabo, Christopher Harbison, Teresa Sanchez, Han Chang, Dimple Pandya, Nathan O. Siemers, Ming Lei
Supplementary Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9522537b32eed18f18dcf3a1c1097324
https://doi.org/10.1158/1078-0432.22481259.v1
https://doi.org/10.1158/1078-0432.22481259.v1